Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New immunosuppressive strategies

P A Keown1

  • 1Department of Medicine, Vancouver General Hospital, BC, Canada. keown@unixg.ubc.ca

Current Opinion in Nephrology and Hypertension
|December 29, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond HLA: An adaptive nanopore sequencing assay for simultaneous HLA and blood group profiling in transplantation.

Human immunology·2026
Same author

Simulation of prospective PIRCHE-II molecular matching in Canada: a feasibility study.

Frontiers in immunology·2026
Same author

Association of gastrointestinal events with quality of life and treatment satisfaction in osteoporosis patients: results from the Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC OS).

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

The Human Proteome Organization Chromosome 6 Consortium: integrating chromosome-centric and biology/disease driven strategies.

Journal of proteomics·2013
Same author

Giving and taking: the family doctor and organ transplantation.

Canadian family physician Medecin de famille canadien·2011
Same author

The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation.

Kidney international·2007
Same journal

Sex differences in renal acid-base regulation.

Current opinion in nephrology and hypertension·2026
Same journal

Primary prevention of chronic kidney disease in type 2 diabetes mellitus with sodium-glucose cotransporter 2 inhibitors.

Current opinion in nephrology and hypertension·2026
Same journal

Financial and policy challenges of delivering kidney replacement therapies in resource-limited settings.

Current opinion in nephrology and hypertension·2026
Same journal

The role of kir4.1/Kir5.1 in mediating the effect of angiotensin-II on Na-Cl-cotransporter.

Current opinion in nephrology and hypertension·2026
Same journal

Role of the calcium-sensing receptor in regulating calcium transport in the thick ascending limb.

Current opinion in nephrology and hypertension·2026
Same journal

Social determinants of chronic kidney disease: from association to clinical and population action.

Current opinion in nephrology and hypertension·2026
See all related articles

Novel immunosuppressive therapies control graft rejection by targeting lymphocyte activation. While effective in the short term, these treatments do not demonstrate long-term graft survival benefits, necessitating new research directions.

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Advancements in immunosuppressive therapy have improved control of graft rejection.
  • Novel agents target specific molecular pathways in lymphocyte activation.

Purpose of the Study:

  • To review current biological and pharmaceutical agents for immunosuppression.
  • To discuss pharmacokinetic factors influencing drug efficacy.
  • To highlight the need for research into long-term immunosuppression strategies.

Main Methods:

  • Review of monoclonal antibodies targeting CD3 and IL-2 receptors.
  • Analysis of biological blockade of co-stimulatory molecules (CD40L, CD28).
  • Evaluation of pharmacokinetic profiles of cyclosporine, tacrolimus, mycophenolate mofetil, and sirolimus.

Related Experiment Videos

  • Discussion of pharmacokinetic and pharmacodynamic monitoring.

    • Main Results:

    • Monoclonal antibodies block T-cell function without inducing cytokine release syndrome.
    • Biological blockade of co-stimulatory molecules shows promise for allograft unresponsiveness in primates.
    • Microemulsion technology enhances cyclosporine absorption and efficacy.
    • Mycophenolate mofetil is effective in combination therapy and at rejection onset.
    • Sirolimus inhibits IL-2 driven proliferation and reduces acute rejection rates.

    Conclusions:

    • Current immunosuppressive therapies effectively manage acute graft rejection but lack demonstrable long-term benefits for graft survival.
    • Pharmacokinetic interactions are significant and require monitoring.
    • Further research is needed to identify targets for effective long-term immunosuppression and improve chronic graft injury outcomes.